PT - JOURNAL ARTICLE AU - Pradip Paul AU - Ravi Kumar Nadella AU - Somdatta Sen AU - Dhruva Ithal AU - Jayant Mahadevan AU - Y C Janardhan Reddy AU - Sanjeev Jain AU - Meera Purushottam AU - Biju Viswanath TI - Association study of <em>BDNF</em> Val66Met gene polymorphism with bipolar disorder and lithium treatment response in Indian population AID - 10.1101/2020.09.28.20203513 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.28.20203513 4099 - http://medrxiv.org/content/early/2020/09/29/2020.09.28.20203513.short 4100 - http://medrxiv.org/content/early/2020/09/29/2020.09.28.20203513.full AB - Background The association of the Val66Met (rs6265) polymorphism in the brain derived neurotrophic factor (BDNF) gene with bipolar disorder (BD) and response to lithium treatment has been suggested, though inconsistently. The considerable diversity of allele frequency across different populations contributes to this. There is no data from South Asia till date. Hence, we examined the association of this polymorphism in BD cases from India, and its correlation with lithium treatment response.Methods BD patients (N=301) were recruited from the clinical services of National Institute of Mental Health and Neurosciences (NIMHANS), India. Lithium treatment response for 190 BD subjects was assessed using Alda scale by NIMH life charts. Patients with total score ≥ 7 were defined as lithium responders (N=115) and patients with score &lt;7 were defined as lithium non-responders (N=75). Healthy controls (N = 484) with no lifetime history of neuropsychiatric illness, or a family history of mental illness were recruited as control set. Genotyping was performed by TaqMan genotyping assay.Results Genotype and allele frequency of BDNF Val66Met SNP was significantly different (χ2 = 7.78, p=0.02) in cases compared to controls, and the Val(G) allele was more frequent (χ2 = 7.08, p=0.008) in BD patients. Although there was trend towards significance for greater occurrence of Val(G) allele among lithium non-responders, this difference did not persist in an analysis of extreme response groups.Conclusions The Val(G) allele of BDNF Val66Met polymorphism is associated with risk of BD in this sample, but is not related to response to lithium.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Department of Biotechnology (DBT), India, funded Centre of Excellence (COE) grants- Targeted generation and interrogation of cellular models and networks in neuro-psychiatric disorders using candidate genes (BT/01/CEIB/11/VI/11/2012) and Accelerating program for discovery in brain disorders using stem cells (BT/PR17316/MED/31/326/2015) (ADBS); Department of Science and Technology (DST), India funded grants- Imaging-genomics approach to identify molecular markers of Lithium response in Bipolar disorder through the DST-INSPIRE Faculty Fellowship awarded to Dr. Biju Viswanath (Project number 00671, Code: IFA-12-LSBM-44). PP was initially funded by DBT-COE and currently being funded by DBT-ADBS and SS was funded by DST-INSPIRE project. RKN and DI is funded by DBT-ADBS. Much of the sample identification was performed using a previous DST funded grant- Generativity in cognitive networks (SR/CSI/44/2008(4)). This work was part of PPs doctoral thesis and the result of this work have been partially presented in conferences- at 19th Annual Conference of the International Society for Bipolar Disorder (ISBD), Washington DC, USA, 2017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee (IEC), NIMHANS had approved the study protocol (NIMHANS IEC No.-Sl. No. 11, Behavioral Science; dated 12th Aug, 2013)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData not available currently